Mylan Recalls Alprazolam Tablets
The company is recalling Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance.
Mylan Pharmaceuticals announced on October 25, 2019 that it was voluntarily recalling one lot of Alprazolam Tablets, USP C-IV 0.5 mg because of potential presence of foreign substance. The recalled lot, number 8082708, was packaged in bottles of 500 and was distributed in the United States between July 2019 and August 2019. Alprazolam Tablets are used to treat anxiety and panic disorder, with or without agoraphobia.
While the company stated in a press release that it had not received any complaints of adverse events related to the recalled lot and that clinical impact from the foreign material would be rare, the risk of infection cannot be ruled out. Adverse events may be reported to FDA through the agency’s MedWatch program.
Source: FDA
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
